CDH2 and diabetes mellitus: Drp1 is increased in endometrial cancer patients with diabetes, and high glucose activates Drp1 in endometrial cancer to induce mitochondrial dysfunction, cellular progression through the cell cycle, increased migration and invasion, and expression of an EMT phenotype (decreased E-cadherin; increased N-cadherin, vimentin, and SNAIL) (54).